Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Clinical Trial ID NCT00994500

PubWeight™ 5.32‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00994500

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 2011 1.05
2 A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol 2013 0.96
3 A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol 2013 0.95
4 The rationale for targeted therapies in medulloblastoma. Neuro Oncol 2013 0.92
5 Medulloblastoma development: tumor biology informs treatment decisions. CNS Oncol 2015 0.78
6 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
Next 100